Abbott Laboratories News
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
see moreAbbott Laboratories Market News
10d
Abbott Laboratories Posts Strong Q3 Earnings and Confirms Nutrition Business Spinoff
- Abbott’s Q3 2026 results show 14.5% sales growth and reaffirmed EPS guidance, alongside plans to spin off its nutrition business into a standalone public company.
24d
Institutional Interest Surges: Seven Investment Managers Buy Abbott (ABT) Shares in Past Month
Seven investment firms have acquired Abbott Laboratories (ABT) stock over the past 30 days, signaling renewed institutional interest in the S&P 500 healthcare name.
26 Sep at 13:24
Abbott Laboratories Settles Investor Lawsuit Over Infant Formula Safety Claims
Abbott Laboratories agreed to a $385 million settlement in a federal investor lawsuit related to safety claims at its Michigan infant formula facility.
12 Sep at 13:24
FDA Clears Abbott’s TactiFlex™ Duo Catheter: A Boost for Medical Devices Segment
FDA has approved Abbott’s TactiFlex Duo ablation catheter, combining RF and pulsed-field ablation for heart rhythm treatment—a key development in its medical devices business.
29 Aug at 13:24
Abbott Laboratories Earns Key Regulatory Approvals in Past Week as Stock Dips Amid Broader Market Weakness
Abbott received CE mark for its Amulet 360™ device and FDA authorization for its dual glucose‑ketone sensor—important milestones as ABT stock slipped ~2.2%.